Kelzy

Dienogest/Ethinylestradiol, the active ingredient in Kelzy, is a combined oral contraceptive presented as an oral tablet for oral use. It works by suppressing ovulation and altering the endometrium to prevent implantation, providing reliable pregnancy prevention for women of reproductive age.

GNH USA supplies Kelzy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution of this EU‑marketed hormonal contraceptive. The product meets European Union regulatory standards and is manufactured under GMP conditions, and is packaged with appropriate patient information.

Kelzy, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

Prevention of unintended pregnancy: provides reliable contraception for women seeking to avoid pregnancy. Family planning: enables controlled fertility management as part of reproductive health. Hormonal contraception: suppresses ovulation and stabilizes the endometrial lining to reduce breakthrough bleeding.

Kelzy may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset that often resolves with continued use. - Headache: tension‑type or migraine‑like headaches. - Breast tenderness: temporary discomfort or swelling of the breasts. - Irregular bleeding: spotting or breakthrough bleeding, especially during the first cycles.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Severe hypertension: sudden increase in blood pressure that may lead to complications. - Liver dysfunction: jaundice, hepatitis, or abnormal liver enzyme levels. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Before prescribing Kelzy, consider the following precautions and warnings.

- Contraindicated in women with a history of venous thromboembolism: avoid use due to clot risk. - Not for smokers over age 35 who smoke >15 cigarettes per day: increased cardiovascular risk. - Avoid during pregnancy: hormonal contraceptives are not indicated for pregnant women. - Caution in breastfeeding mothers: may affect milk production and infant exposure. - Use with caution in patients with liver disease: impaired metabolism may increase side effects. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Kelzy can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness. - Anticoagulants (e.g., warfarin): estrogen component can enhance clotting factor synthesis, potentially altering anticoagulant control. - High‑dose selective serotonin reuptake inhibitors (e.g., fluoxetine): may increase plasma levels of ethinylestradiol, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): can increase estrogen levels, requiring monitoring for adverse effects. - Antiretroviral drugs (e.g., protease inhibitors): may affect hormone metabolism, necessitating efficacy monitoring. - St. John’s wort herbal supplement: may reduce hormonal levels, decreasing contraceptive reliability.